Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
Zk1rkaxm5M2mA8k6
